Oxford Biomedica

oxford biomedica plc (lse: oxb) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. our technology platforms include a highly efficient lentivector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5t4), which is an ideal target for anti-cancer therapy. through in-house and collaborative research, we have a broad pipeline with current partners and licensees including sanofi, pfizer, novartis, glaxosmithkline, molmed, sigma-aldrich, biogen idec, emergent biosolutions and imaginab and immune design corp.